Trimektal MR, pills 35mg, 120pcs

Composition

1 tablet contains trimetazidine dihydrochloride-0.035 g;

excipients:

collidone SR [polyvinyl acetate 80%,

povidone 19%,

sodium lauryl sulfate 0.8%,

silicon dioxide 0.2%],

calcium hydrophosphate dihydrate,

silicon dioxide colloidal (aerosil),

magnesium stearate;

film coating:

hypromellose (hydroxypropylmethylcellulose),

talc,

titanium dioxide,

macrogol 4000 (polyethylene oxide 4000 or polyethylene glycol 4000) or Advantia Prime film shell 390009ZA09-white (hypromellose, talc, titanium dioxide, macrogol 4000).

Pharmacological action

Trimectal MV is a universal anti-ischemic drug. It has an antianginal, antihypoxic effect. Directly affecting cardiomyocytes and brain neurons, it optimizes their metabolism and function. The cytoprotective effect is due to an increase in the energy potential, activation of oxidative decarboxylation, and rationalization of oxygen consumption (increased aerobic glycolysis and blockade of fatty acid oxidation).

Trimectal supports myocardial contractility, prevents a decrease in the intracellular content of ATP and phosphocreatinin; In conditions of acidosis, it normalizes the functioning of membrane ion channels, prevents the accumulation of calcium and sodium in cardiomyocytes, and normalizes the intracellular content of potassium ions;

Reduces intracellular acidosis and phosphate levels due to myocardial ischemia and reperfusion.

It promotes the damaging effect of free radicals, preserves the integrity of cell membranes, prevents neutrophil activation in the ischemic zone, increases the duration of the electrical potential, reduces the release of creatine phosphokinase from cells and the severity of ischemic myocardial damage.

When angina reduces the frequency of attacks (reduces the intake of nitrates), after 2 weeks of treatment increases tolerance to physical activity, decreases blood pressure drops.

Hearing and vestibular test results are improved in patients, dizziness and tinnitus are reduced.

In vascular pathology, the eye restores the functional activity of the retina.

Indications

Coronary heart disease: prevention of angina attacks (in complex therapy); Cochleovestibular disorders of an ischemic nature, such as dizziness, tinnitus, hearing impairment.

In ophthalmology:  chorioretinal vascular disorders with ischemic components.

Contraindications

Hypersensitivity to any component of the drug;

Renal insufficiency (creatinine clearance below 15 ml / min);

Severe liver function disorders;

Pregnancy; breast-feeding period;

Age up to 18 years (efficacy and safety have not been established).

Side effects

Allergic reactions: pruritus, urticaria; 

From the gastrointestinal tract:  gastralgia, diarrhea, nausea, vomiting (rare).

From the central nervous system:  often – dizziness, headache, asthenia; very rarely-extrapyramidal disorders (tremor, rigidity, akinesia), reversible after discontinuation of the drug.

From the cardiovascular system:  rarely-orthostatic hypotension, “hot flashes” of blood to the skin of the face.

Interaction

Clinical studies of trimetazidine have shown that it increases the anti-ischemic activity of other antianginal drugs, but no other interactions were observed.

How to take, course of use and dosage

Inside, during a meal.

Trimectal is taken 1 tablet 2 times a day (morning and evening).

Course of treatment according to the doctor’s recommendation.

Overdose

Currently, no cases of overdose of Trimectal MV have been reported.

Special instructions

Do not use for relief of angina attacks. The drug is not indicated for the initial course of treatment of unstable angina or myocardial infarction. If an angina attack develops, the treatment should be reviewed and adapted.

Against the background of treatment with the drug in patients with coronary heart disease, a significant decrease in the daily need for nitrates occurs.

The use of the drug does not affect the ability to drive a car and perform work that requires a high speed of mental and physical reactions.

Form of production

Modified release film-coated tablets.

Storage conditions

Store in a dry place, protected from light, at a temperature not exceeding 25 °C

Shelf life

2 years

Active ingredient

Trimetazidine

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Description

For adults as directed by your doctor

Indications

Angina, Vascular diseases of the eyes